Top of the morning to you, and a fine one it is, as the much-discussed change in Washington, D.C., offers the U.S. a fresh start on combating Covid-19, among many other things. Quite a to-do list, yes? Well, we will celebrate with a few cups of stimulation — maple bourbon is our choice today — and we invite you to join us. Meanwhile, time to get cracking. Here are a few tidbits to help you get going. We hope your day is productive and meaningful. And if you come across any juicy tidbits or secret dossiers, keep us in mind. …

The Covid-19 vaccine from Pfizer (PFE) and BioNTech (BNTX) appears to work just as well against a fast-spreading variant of Covid-19 first identified in the U.K. as it does against earlier forms of the virus, STAT writes. The findings, based on an analysis of blood of participants in trials, are based on more extensive analysis than those released last week. Pfizer said a similar lab study showed the vaccine was effective against one key mutation, called N501Y, found in both of the highly transmissible new variants spreading in the U.K. and South Africa.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]